PHARMAGEN INC

PHARMAGEN INC

OOTC:PHRX
0.00
USD
0.00
(0.00%)
-0.01EPS
1.92MMarket Cap

Total Valuation

USD

As of March 31, 2014, PHARMAGEN INC carries a market capitalization of 1.92M, placing it among publicly traded companies globally. Its enterprise value stands at 7.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.92M
Enterprise Value7.39M

Share Statistics

As of March 31, 2014, PHARMAGEN INC has 504.45M shares outstanding.

Shares Outstanding504.45M

Valuation Ratios

These figures are as of March 31, 2014. The price-to-sales ratio is 0.36, and the price-to-book ratio stands at -0.24.

PS Ratio0.36
PB Ratio-0.24
P/TBV Ratio-0.24
P/FCF Ratio-2.71
P/OCF Ratio-3.29

Enterprise Valuation

These figures are as of March 31, 2014. The EV/Sales ratio of 1.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.39M versus a market cap of 1.92M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.67

Financial Position

As of March 31, 2014, PHARMAGEN INC maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -71.34, indicating conservative leverage, while an interest coverage ratio of -1.19 demonstrates limited ability to service its debt obligations.

Current Ratio0.10
Quick Ratio0.07
Debt / Equity-71.34
Debt / EBITDA-1.60
Interest Coverage-1.19

Financial Efficiency

USD

These figures cover the twelve months ended March 31, 2014. Return on assets (ROA) is negative at -246.83, reflecting losses generated across the asset base. The company generates approximately 2.21M in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.45 indicates how many times PHARMAGEN INC sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-246.83
Revenue Per Employee2.21M
Employee Count2.00
Inventory Turnover9.45

Stock Price Statistics

USD

As of the close on November 16, 2026, PHARMAGEN INC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at -NaN, while the 200-day moving average is 0.00.

50-Day Moving Average-NaN

Income Statement

USD

Over the twelve months ended March 31, 2014, PHARMAGEN INC generated 4.41M in revenue and converted that into -5.87M in net income, yielding earnings per share of -0.01. EBITDA reached -3.59M, while operating income came in at -2.24M.

Revenue4.41M
Gross Profit2.75M
Operating Income-2.24M
Net Income-5.87M
EBITDA-3.59M
EBIT-3.69M
Earnings Per Share (EPS)-0.01

Balance Sheet

USD

As of March 31, 2014, PHARMAGEN INC holds 264,673.00 in cash and equivalents against 5.73M in total debt, resulting in a net debt position of 5.15M. Total book value stands at -8.03M, with working capital of -7.46M providing operational flexibility.

Cash & Cash Equivalents264,673.00
Total Debt5.73M
Net Debt5.15M
Equity (Book Value)-8.03M
Book Value Per Share-0.02
Working Capital-7.46M

Cash Flow

USD

PHARMAGEN INC produced -483,093.00 in operating cash flow over the twelve months ended March 31, 2014. After subtracting -102,607.00 in capital expenditures, free cash flow totaled -585,700.00 - equivalent to 0.00 per share.

Operating Cash Flow-483,093.00
Capital Expenditures-102,607.00
Free Cash Flow-585,700.00

Margins

Over the twelve months ended March 31, 2014, PHARMAGEN INC posted a gross margin of 62.35, reflecting its pricing power and cost economics. The operating margin of -50.83 and net profit margin of -133.10 provide insight into operational efficiency.

Gross Margin62.35
Operating Margin-50.83
Profit Margin-133.10
EBITDA Margin-81.36

Dividends & Yields

These figures cover the twelve months ended March 31, 2014. The dividend payout ratio of 1.67 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -36.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.61, meaning PHARMAGEN INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio1.67
Shareholder Yield-10.61
FCF Yield-36.90

Stock Splits

PHARMAGEN INC's most recent stock split took place on December 7, 2011 with a 1:45 split ratio.

Last Split Date12/7/2011
Split Ratio1:45

Scores

As of March 31, 2014, PHARMAGEN INC has an Altman Z-Score of -20.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-20.29